Download PDF
Deutsche Zeitschrift für Onkologie 2021; 53(01): 8-11
DOI: 10.1055/a-1394-1519
Forschung

Die Misteltherapie beim Mammakarzinom und Fatigue

Mistletoe Therapy for Breast Cancer and Fatigue
Daniela Paepke
1   Interdisziplinäres Brustzentrum, Frauenklinik rechts der Isar, TU München
› Author Affiliations
› Further Information
    Permissions and Reprints

Zusammenfassung

Die Mistel gehört in Deutschland zu den meistverordneten komplementärmedizinischen Krebsmedikamenten. Viele Patientinnen mit Mammakarzinom erhalten im Verlauf ihrer Erkrankung eine Misteltherapie. Präklinische Forschungen, klinische Studien und Übersichtsarbeiten liegen zum Einsatz der Misteltherapie beim Mammakarzinom vor. Hautsächlich findet die Mistel Anwendung bei Tumor-assoziierter Fatigue, zur Verbesserung der Lebensqualität und zur Verminderung systemtherapeutisch bedingter Nebenwirkungen.

Abstract

Mistletoe is one of the most widely prescribed complementary cancer drugs in Germany. Many patients with breast cancer receive mistletoe therapy in the course of their illness. Preclinical research, clinical studies and reviews are available on the use of mistletoe therapy in breast cancer. Mistletoe is mainly used for tumor-associated fatigue, to improve the quality of life and to reduce side effects caused by system therapy.

Schlüsselwörter

Fatigue - Mammakarzinom - Misteltherapie - Lebensqualität - Therapiekombinationen - Sicherheit

Key words

Fatigue - breast cancer - mistletoe therapy - quality of life - therapy combinations - safety


Publication History

Article published online:
01 April 2021

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Yancey J, Thomas S. Chronic fatigue syndrome: diagnosis and treatment. Am Fam Physician 2012; 86: 741-746
    PubMedGoogle Scholar
  • 2 Berger A, Mooney K, Alvarez-Perez A. et al. National comprehensive cancer network. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw 2015; 13: 1012-1039
    CrossrefPubMedGoogle Scholar
  • 3 Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). www.ago-online.de 2020
    PubMed
  • 4 Anonymus. Ein neues Krebsheilmittel. Cancerodoron. Neues Wiener Journal 1924; 11. Januar 1924
    PubMed
  • 5 Hoffmann F. Versorgung mit Krebstherapeutika im Jahr 2010. In: Glaeske G, Schicktanz C. Schriftenreihe zur Gesundheitsanalyse. Schwäbisch Gmünd: Barmer GEK; 2011
    Google Scholar
  • 6 Wilkens J. Misteltherapie: Differenzierte Anwendung der Mistel nach Wirtsbäumen. Stuttgart: Sonntag; 2006
    Google Scholar
  • 7 Bopp A. Die Mistel – Heilpflanze in der Krebstherapie. Zürich: Rüffer & Rub; 2006
    Google Scholar
  • 8 Wilkens J. Misteltherapie. Differenzierte Anwendung der Mistel nach Wirtsbäumen. Stuttgart: Sonntag-Verlag; 2006: 156
    Google Scholar
  • 9 Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev 2008; 2008: CD003297 DOI: 10.1002/14651858.CD003297.pub2.
    CrossrefPubMedGoogle Scholar
  • 10 Tröger W, Jezdić S, Zdrale Z. et al. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer (Auckl) 2009; 3: 35-45
    PubMedGoogle Scholar
  • 11 Tröger W, Zdrale Z, Tisma N, Matijasevic M. Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: An open randomized clinical pilot trial. Evid Based Complement Alternat Med 2014; 2014: 430518
    CrossrefPubMedGoogle Scholar
  • 12 Pelzer F, Tröger W, Nat DR. Complementary treatment with mistletoe extracts during chemotherapy: Safety, neutropenia, fever, and quality of life assessed in a randomized study. J Altern Complement Med 2018; 24: 954-961
    CrossrefPubMedGoogle Scholar
  • 13 Tröger W, Zdrale Z, Stankovic N, Matijasevic M. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl) 2012; 6: 173-180
    PubMedGoogle Scholar
  • 14 Tröger W, Zdrale Z, Stankovic N. Fünf-Jahres-Nachbeobachtung von Patientinnen mit Brustkrebs nach einer randomisierten Studie mit Viscum album (L.) Extrakt. Dtsch Z Onkol 2016; 48: 105-110 DOI: 10.1055/s-0042-113505.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Eisenbraun J, Scheer R, Kroz M. et al. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine 2011; 18: 151-157
    CrossrefPubMedGoogle Scholar
  • 16 Loewe-Mesch A, Kuehn J, Borho K. et al. Adjuvant simultaneous mistletoe chemotherapy in breast cancer – influence on immunological parameters, quality of life and tolerability. Forsch Komplementmed 2008; 15: 22-30
    CrossrefPubMedGoogle Scholar
  • 17 Bar-Sela G, Wollner M, Hammer L. et al. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer 2013; 49: 1058-1064
    CrossrefPubMedGoogle Scholar
  • 18 Bock PR, Friedel WE, Hanisch J. et al. Efficacy and safety of long-term complementary treatment with standardised European mistletoe extract (VISCUM ALBUM L.) in addition to the conventional adjuvant oncological therapy in patients with primary non-metastatic breast cancer. Arzneimittel-Forschung/Drug Research 2004; 54: 456-466
    PubMedGoogle Scholar
  • 19 Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med 2012; 2012: 219402
    CrossrefPubMedGoogle Scholar
  • 20 Beuth J, Schneider B, Schierholz JM. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res 2008; 28: 523-527
    PubMedGoogle Scholar
  • 21 Kienle GS, Glockmann A, Schink M, Kiene H. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 2009; 28: 79
    CrossrefPubMedGoogle Scholar
  • 22 Nazaruk J, Orlikowski P. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res 2016; 30: 373-385
    CrossrefPubMedGoogle Scholar
  • 23 Oei SL, Thronicke A, Schad F. Mistletoe and immunomodulation: Insights and implications for anticancer therapies. Evid Based Complement Alternat Med 2019; 2019: 5893017
    PubMedGoogle Scholar
  • 24 Büssing A, Schietzel D, Schietzel M. et al. Keine Stimulation in vitro kultivierter Tumorzellen durch Mistellektin. Dtsch. Z Onkol 2004; 36: 66-70 DOI: 10.1055/s-2004-828263.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Mansky PJ, Wallerstedt DB, Sannes TS. et al. NCCAM/NCI Phase 1 study of mistletoe extract and Gemcitabine in patients with advanced solid tumors. Evid Based Complement Alternat Med 2013; 2013: 964592
    CrossrefPubMedGoogle Scholar
  • 26 Weissenstein U, Kunz M, Urech K, Baumgartner S. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complement Altern Med 2014; 14: 6
    CrossrefPubMedGoogle Scholar
  • 27 Hong CE, Park AK, Lyu SY. Synergistic anticancer effects of lectin and doxorubicin in breast cancer cells. Mol Cell Biochem 2014; 394: 225-235
    CrossrefPubMedGoogle Scholar
  • 28 Beuth J, Kelter G, Fischer U. et al. Tumorwachstumsstimulation durch Mistelpräparate? Fakten und Artefakte. Dtsch Z Onkol 2008; 40: 12-19 DOI: 10.1055/s-2008-1044045.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Burger AM, Mengs U, Kelter G. et al. No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro. Anticancer Res 2003; 23: 3801-3806
    PubMedGoogle Scholar
  • 30 Weissenstein U, Kunz M, Oufir M. et al. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Complement Altern Med 2019; 19: 23
    CrossrefPubMedGoogle Scholar
  • 31 Weissenstein U, Kunz M, Urech K. et al. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med 2016; 16: 271
    CrossrefPubMedGoogle Scholar
  • 32 Greenlee H, DuPont-Reyes MJ, Balneaves LG. et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017; 67: 194-232
    CrossrefPubMedGoogle Scholar
  • 33 Lyman GH, Greenlee H, Bohlke K. et al. Integrative therapies during and after breast cancer treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol 2018; 36: 2647-2655
    CrossrefPubMedGoogle Scholar
  • 34 Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). Leitlinien/Empfehlungen: Komplementäre Therapie. Stand: 02.03.2020 www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2020/PDF_DE/2020D%2023_Komplementaermedizin.pdf
    PubMed